EXECUTIVE INTERVIEWS

• Building GSK Oncology R&D

  Axel Hoos, M.D., Ph.D., SVP oncology and R&D governance chair, provides an update and the context of GSK’s R&D strategy.

• The Story Of Arrowhead Pharmaceuticals’ Adversity Odyssey

  Chis Anzalone, Ph.D., CEO of Arrowhead Pharmaceuticals, discusses taking over a biopharmaceutical company shortly before the Great Recession along with other avenues of adversity faced (e.g., FDA hold on a Phase 2 trial) toward bringing this RNAi company to the brink of success.

• Why You Need People Like Jana Spes At Your Company

  Industry veteran Jana Spes provides some uniquely qualified analysis and guidance on the outsourcing industry and working with CDMOs. Don’t be surprised if you come away thinking for your next outsourcing operations hire, specialization is out, and the Spes model is in.

• Jeff Albers’ Blueprint For Blueprint Medicines

  Jeff Albers, president and CEO of Blueprint Medicines, discusses his approach to ensuring the biopharma is commercial ready should it garner some pivotal FDA approvals.

• A Biopharma That Had To Pivot Twice To Forge Ahead

  Not many thriving companies experience disappointing clinical trial results, jump into an entirely new therapeutic area, and emerge with investor support and renewed hope for an entirely different class of patients. Millendo has done it twice.

• The Perilous Development Of A Potential Biologic Blockbuster

  CytoDyn's leronlimab is under FDA review for Breakthrough Therapy status. Its path from forgotten molecule to near market readiness was riddled with financial and process challenges.

• Allogene Therapeutics — The Juggernaut Built On Kite’s Flight

  David Chang, M.D., Ph.D., CEO and cofounder of Allogene Therapeutics, shares how the successful exit from Kite Pharma (acquired by Gilead for $11.9 billion in 2017) led to the building of Allogene, a $3.4 billion clinical-stage biopharma developing allogeneic CAR-T therapy.

• Why John Sculley Views Healthcare As His “Noble Cause”

  John Sculley, the former CEO of Apple who is now an entrepreneur and investor in high-tech startups, discusses where he sees opportunity in the healthcare industry, along with the leaders he views as being just as visionary as Steve Jobs, if not more so.

• J&J And Merck Detail How They Are Investing For Impact

  Two Big Pharma executives explain how their organizations are investing for impact.

• Women On Boards: How We Get From Here To There

  Even though females have “arrived” as biotech executives, there’s more to be done: serving as CEOs, advisors, and directors to help companies achieve their missions.

• The 5-Step Strategy That Saved Genmab From A Dire Outlook

  Jan G. J. van de Winkel, Ph.D., cofounder, president, and CEO since 2010, remembers when Genmab faced some pretty tough decisions.

• What 9 Biopharma Trendsetters Expect For 2020 – And Beyond

  Although AI, machine learning, and quantum computing will someday improve our ability to forecast the future, for now Life Science Leader continues to seek knowledge from a cross section of life sciences industry execs.

• Biotechs Will Make Music In The “Twenty-Twenties”

  Outsourced Pharma Chief Editor Louis Garguilo talks with two biotech CEOs about why they believe this industry should expect an infusion of technology and improved productivity in the coming years.

• Competing Interests Complicate FDA Reform

  With input from two long-time observers of the biopharma industry and its U.S. regulator, this article covers a cross-section of opinions regarding trends and proposals for improving the FDA review process.